A comprehensive view of Boehringer Ingelheim GmbH. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
Boehringer Ingelheim partners with Shanghai RAAS for the development and clinical production of hemophilia drug SR604 injection; the drug has received approval for Phase I clinical trial targeting hemophilia and congenital factor VII deficiency
Published:
March 21, 2024
by Contify Life Science News
|
AAFA releases statement on asthma inhaler price caps, advocates for change in drug pricing to make medicines more affordable; group lauds Boehringer Ingelheim's US$35 per month cap on out-of-pocket costs for its COPD and asthma inhaler portfolio
Published:
March 08, 2024
by GlobeNewswire
|
Boehringer Ingelheim to cap US patients' out-of-pocket costs for inhaler products at US$35 per month, reduce certain list prices and continue significant discounts to insurers; the move follows criticisms of high inhaler costs by a US Senate committee
Published:
March 08, 2024
by FiercePharma
|
Boehringer Ingelheim commits €120.0M to expand its Koropi, Greece, plant to boost Jardiance production and increase capacity for certain drugs in late-stage development; the expansion is expected to add 110 new jobs
Published:
January 12, 2024
by FiercePharma
|
Boehringer Ingelheim and 3T Biosciences enter into US$538.5M deal to develop new cancer immunotherapies; 3T will provide patient-derived TCR data for Boehringer's TcEs, oncolytic viruses, and cancer vaccine research
Published:
January 08, 2024
by Marketline - Deals
|
Ask us about our Health Care Sector market view